Stock Scorer

Lakefront Biotherapeutics NV (LKFT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in EUR. Every figure as a table ›

Revenue Quarterly

0 50M 100M 150M Q2 '17: 26.9M Q2 '18: 49.7M Q2 '19: 58.7M Q2 '20: 99.6M Q2 '21: 139.8M Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '21

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q2 '17: -21.7M Q2 '18: -33.8M Q2 '19: -44.4M Q2 '20: -88.2M Q2 '21: -46.8M Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '21

Net Income Quarterly

-120M -80M -40M 0 40M 80M 120M Q2 '17: -35.6M Q2 '18: -21.8M Q2 '19: -47.2M Q2 '20: -115M Q2 '21: -64.3M Q2 '17 Q2 '18 Q2 '19 Q2 '20 Q2 '21

EPS Annual

-4.00 -2.00 0.00 2.00 4.00 6.00 FY21: -1.58 FY22: -3.32 FY23: 3.21 FY24: 1.12 FY25: 4.87 FY21 FY22 FY23 FY24 FY25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for LKFT: Gross Profit, Cost of Revenue, Operating Cash Flow, Free Cash Flow, Shares Outstanding. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.